Actoprotector (adamantane derivative)
Bromantane
Bromantane after one dose: 50% at ~12 h, 25% at 24 h, 12.5% at 36 h.
Drawn from the half-life in the app's model, ~12 h. The model's figures
- Compound
- Bromantane
- Symbol
- BRM
- Family
- Cognitive and sleep peptides
- Parts
- 13
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Bromantane, with the chemical name N-(2-adamantyl)-N-(para-bromophenyl)-amine, is an adamantane derivative that Oliynyk and Oh say is regarded in the literature as an actoprotector.3 Oliynyk and Oh, in a 2012 review in Biomolecules and Therapeutics, write that of all actoprotectors only two are permitted for medical use, and that bromantane is sold as Ladasten and "certified in Russia as a drug".3 The app's notes state that it is not approved anywhere else. No label for bromantane was identified in DailyMed, and no entry was identified in ClinicalTrials.gov, in searches run on 16 November 2026 for "bromantane" and "ladasten".
The same review describes a compound "which possesses combined stimulative and anxiolytic effects".3 A 1997 letter in The Lancet from Burnat and colleagues is titled "Bromontan, a new doping agent".4 The app's notes add that the letter reported it as a doping agent partly because its resemblance to amantadine evaded stimulant screens; the PubMed record holds only the title and authors, so that detail is not checked here.4 The app grades the evidence for bromantane as anecdotal.
The human evidence retrieved is a set of Russian clinical studies, mainly of asthenic, neurasthenic and anxiety-asthenic disorders, with one record each on Parkinson's disease and irritable bowel syndrome, all available here only as PubMed records. Their full texts were not retrieved, so sample sizes, effect sizes and funding are given only where the PubMed record states them. No controlled trial in people from outside Russia was identified in PubMed or ClinicalTrials.gov.
How it works
All mechanistic findings retrieved are from animals or from tissue, and none is from a human study.
Kudrin and colleagues, Experimental and Clinical Pharmacology, 1995, gave rats bromantane at 50 mg/kg by mouth, acutely and chronically, and measured norepinephrine, dopamine and serotonin and their metabolites.5 They report that bromantan "induced a significant increase in the 5-HT and 5-HIAA content in the frontal cortex and delayed an increase in their content in subcortical brain regions", with a stable decrease in cerebellar serotonin and 5-HIAA.5 They conclude that the dopamine findings suggest "an important role of dopaminergic system in the mechanism of pharmacological effects of the drug".5
A companion 1995 paper by Grekhova and colleagues, a microdialysis study in freely moving rats, is titled as a study of bromantane's effect on "release and metabolism of dopamine in the dorsal striatum".6 The app's notes describe a prolonged 8-hour rise in striatal dopamine release from that work; the PubMed record retrieved has no summary text, so the 8-hour figure is not checked here.6
Vakhitova and colleagues, Experimental and Clinical Pharmacology, 2004, studied ladasten at 50 mg/kg and the expression of the genes for tyrosine hydroxylase (TH) and DOPA-decarboxylase (DDC) in rat striatum and hypothalamus.7 They write that "in the initial stage (first hours) of the drug action, the dopaminergic effects are related to an increase in the dopamine release", and conclude that its activity "is related to activation of de novo synthesis of TH and DDC".7 The app's notes say the claim that bromantane upregulates tyrosine hydroxylase and AADC gene expression could not be traced to a primary source; this 2004 rat report is a primary source for a version of it, restricted to rats.7 The record lists the work as "Research Support, Non-U.S. Gov't", and the PubMed record gives no further funding statement.7
Mikhaylova and colleagues, Neuropharmacology, 2007, whose first author is listed at the Leibniz Institute for Neurobiology in Magdeburg, gave rats a single oral dose of 50 mg/kg.8 They report that ladasten "differentially regulates tyrosine hydroxylase mRNA and protein as well as dopamine and L-DOPA content", that 10 microM in vitro transformed short-term potentiation of synaptic transmission into a long-lasting form, and that the same transformation seen when ladasten was applied 40 min after a single tetanization was blocked by the protein synthesis inhibitor anisomycin and could be attenuated by the D1/D5 receptor antagonist SCH23390.8
Morozov and colleagues, Institute of Pharmacology, Russian Academy of Medical Sciences, 1999, describe bromantan as having "psychostimulating activity in experiments on animals", and report a positive effect on memory processes and on complex operant activity in rats.9 The Oliynyk and Oh review states that it "does not exert any expressed action on noradrenergic mediators, but implements the activation properties through the dopaminergic system", and adds that a serotonin effect is assumed; it cites no data retrievable here for those statements.3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~12 h
- Bioavailability
- 85%
- Typical dose
- 50–100 mg/day
- Route
- Oral
- Time to peak
- ~3 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~12 h | No numeric human half-life was identified in the sources retrieved; Oliynyk and Oh state only that "the half-life is respectively lower than in men" for women3 |
| Bioavailability | 85% | 42% by mouth in the Oliynyk and Oh review3 |
| Time to peak | ~3 h | 2.75 hours in women and 4.0 hours in men in the Oliynyk and Oh review3 |
| Duration of action | 16 h | No figure identified in the sources retrieved |
| Route | Oral | Oral in the Oliynyk and Oh review; the Russian trial records give daily doses in mg but name no route3,1 |
The app's notes state that human pharmacokinetics are not established, that no human pharmacokinetic study is indexed in PubMed, and that its half-life, bioavailability and time to peak are modelled by analogy to the adamantane class (amantadine), as an assumption for charting and not a measurement. The app's 85% bioavailability and 12-hour half-life are therefore modelled values, and the review's figures are a different set; the review's own source for them was not available in what was retrieved. The only pharmacokinetic paper the app's notes cite, Sergeeva and colleagues in 1995, is titled "Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane"; the PubMed record has no summary text or numbers, and the app's notes describe it as a rat study.10 Widely repeated 72-hour half-life claims have no traceable source, according to the app's notes.
Oliynyk and Oh describe distribution and handling in these words: bromantane "is highly lipophilic, is distributed into the lipids of brain and fat tissue and, finally, is deposited in adipose tissue".3 They write that metabolism "is characterized mainly by hydroxylation in the 6th position of the adamantan cycle" and that metabolites "can be found in urine, even in two weeks after administration of bromantane (this last fact is important for doping control)".3 No level chart is drawn here, because the sources retrieved report an interval between doses in none of their records.
Human studies
The studies below are all Russian, all retrieved as PubMed records without full text, and none carries a funding statement in the record.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Voznesenskaia and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 20101 | Multicentre study at 28 centres in Russia; the record describes no placebo or comparison group1 | 728 patients with psychoautonomic syndrome and asthenic disorders, 91.6% of the total sample, available for analysis1 | Ladasten 50 to 100 mg daily for 28 days, with follow-up one month after treatment1 | Responders 76.0% on the CGI-S and 90.8% on the CGI-I; adverse effects in 3% of patients, therapy discontinued in 0.8%, no serious adverse effects1 |
| Neznamov and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 200912 | Randomised blind study against placebo, with a wash-out period, 28 days of monotherapy and a final 1-week placebo period12 | Patients with neurasthenia; the record gives no number12 | Ladasten or placebo for 28 days; the record gives no dose12 | Ladasten "superior in the rate and degree of reduction of main symptoms of asthenic syndrome compared to placebo"; no withdrawal syndrome after stopping; no numbers in the record12 |
| Siuniakov and colleagues, Eksp Klin Farmakol 200611 | Listed as Clinical Trial, Phase II; described as a pilot study11 | Patients with psychogenic asthenic disorder; the record gives no number11 | The record mentions single administration only; it gives no dose or length11 | After single administration "the psychostimulant action is predominating", with an anxiolytic effect also reported; no numbers in the record11 |
| Neznamov and colleagues, Eksp Klin Farmakol 200813 | Clinical and EEG analysis by individual EEG type13 | Anxiety-asthenic patients; the record gives no number13 | The record gives no dose or length13 | Effects differed by EEG type: predominantly psychostimulant action with marked alpha rhythm, an anxiolytic-type EEG pattern with reduced alpha rhythm; no significant correlations between baseline EEG results and initial mental condition indices13 |
| Neznamov and colleagues, Eksp Klin Farmakol 201214 | Randomised controlled trial analysis of ladasten and placebo by EEG alpha rhythm type14 | Patients with neurasthenia; the record gives no number14 | Single test doses and long-term treatment; the record gives no dose or length14 | In patients with reduced EEG alpha activity the action of ladasten and placebo "was more robust (the subjective estimation was higher)"; self-assessment of single test doses of both was independent of EEG alpha rhythm and personal traits for tolerability, wish to continue the treatment, and activating and calming effects14 |
| Sarycheva and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 201115 | Listed as a randomised controlled trial; the PubMed record has no summary text15 | Patients with Parkinson's disease, from the title15 | Not available in the record | Not available in the record; the title concerns "non-motor symptoms of Parkinson's disease"15 |
| Uspenskii and Fominykh, Eksp Klin Gastroenterol 201016 | Listed as a clinical trial16 | Patients with irritable bowel syndrome; the record gives no number16 | The record gives no dose or length | The record states only that results of ladasten use in these patients "are presented"16 |
Deeper analysis: the 28-centre multicentre study
Voznesenskaia and colleagues reported in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2010, a study "carried out in 28 clinical centers of Russia".1 Analysis covered 728 patients, 91.6% of the total sample, so about 8.4% of the sample are not in the analysed set, and the record does not say why.1 All had asthenic disorders, and ladasten was given at a daily dose "from 50 to 100 mg" for 28 days, with scale assessments at baseline, on days 3, 7, 14 and 28, and one month after treatment.1 Responder rates were 76.0% on the CGI-S and 90.8% on the CGI-I; the authors write that the antiasthenic effect "was seen on day 3 and remained during one month after the withdrawal of therapy".1 The record describes no placebo or other comparison group, so the responder rates cannot be read as an effect of the drug over no treatment. The record reports no secondary results beyond improvements in quality of life, anxiety-depressive disorders, autonomic dystonia and sleep, again without figures or a comparator.1 On safety the authors write that "Adverse effects were observed only in 3% of patients" and that "No serious adverse effects were found".1 The record does not name the adverse effects, does not report deaths, and states no limitations, funder or author tie to a manufacturer. The authors conclude that 50 to 100 mg daily is "a highly effective, well-tolerated and safety drug"; that conclusion rests on an uncontrolled design as described.1
Deeper analysis: the placebo-controlled neurasthenia study
Neznamov and colleagues reported in the same journal in 2009 a randomised blind study whose stated aim was "to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia".12 The design included a wash-out period, 28 days of monotherapy with ladasten or placebo, and a final 1-week period on placebo.12 The authors report that ladasten was superior to placebo "in the rate and degree of reduction of main symptoms of asthenic syndrome", and that the absence of a "withdrawal syndrome" shows "the lack of addictive potential".12 The record gives no number of participants, no dose, no scale scores, no p-values, no adverse event counts and no discontinuations, so neither the size of the difference nor any null or secondary result can be reported.12 The design described includes a final 1-week period of receiving placebo; the record does not state over what period the absence of a withdrawal syndrome was assessed.12 The record states no limitations, funder or author tie to a manufacturer. A later paper by overlapping authors, Neznamov and colleagues in 2012, analysed ladasten and placebo effects by EEG alpha rhythm type; it reports that self-assessment of single test doses of ladasten and placebo was independent of EEG alpha rhythm and personal traits for tolerability, wish to continue the treatment, and activating and calming effects, and that in patients with reduced alpha activity the action of both "was more robust (the subjective estimation was higher)".14
Doses reported in studies and on labels
No label for bromantane was identified in DailyMed. Doses below are from the Russian trial records and the app.
| Source | Population and design | Dose and length | Reference |
|---|---|---|---|
| App's figure | Not stated | 50 to 100 mg/day, oral | The app's figure |
| Voznesenskaia and colleagues 2010 | 728 patients with psychoautonomic syndrome and asthenic disorders; multicentre, no comparator described | 50 to 100 mg daily for 28 days | PMID 213228211 |
| Neznamov and colleagues 2009 | Neurasthenia; randomised blind, placebo-controlled | 28 days of ladasten or placebo; dose not in the record | PMID 1949181412 |
Sources in this part
The app's notes state that the 50 to 100 mg/day range reflects the Russian tablet strength, not a dose-ranging trial. The Voznesenskaia record is consistent with that range as a daily dose, but it describes no comparison between doses.1
Side effects reported
Voznesenskaia and colleagues report adverse effects in 3% of 728 analysed patients, discontinuation of therapy in 0.8%, and no serious adverse effects.1 The record does not say which adverse effects occurred, and the study as described had no comparison group.1 Neznamov and colleagues listed possible side effects and a "withdrawal syndrome" among the tasks of their placebo-controlled study, and report none after withdrawal, but give no adverse event counts in the record.12 The Oliynyk and Oh review states that bromantane "does not possess any addictive potential" and does not, "unlike typical psychostimulants, develop the phenomena of hyperstimulation"; the review's underlying data are not retrievable here.3 No safety, tolerance or dependence data from any controlled trial with full results were retrieved, as the app's notes also state.1 Acute toxicity records exist. Bugaeva and colleagues, Institute of Pharmacology, Volgograd State Medical Academy, 2000, used conventional acute toxicity tests and behavioural activity data, calculated "levels of therapeutic, toxic, and lethal doses", and concluded that "catecholaminergic effects account for the mechanism of therapeutic action of bromantan, while cholinergic effects determine the drug action in toxic doses"; the record does not name the species.17 Morozov and colleagues give an LD50 of 8100 mg/kg in mice by intraperitoneal injection.9
Bloodwork and markers
Sources in this part
The app lists blood pressure, heart rate and liver enzymes as markers to monitor, with no interaction flags. No human trial record retrieved reports blood pressure, heart rate or liver enzyme results for ladasten. The Oliynyk and Oh review states that bromantane "displays a positive inotropic action without affecting the heart chronotropic function or systemic arterial pressure"; it is a review statement, and the underlying data are not retrievable here.3 The same review states that bromantane "stimulates synthesis of cytochrome P-450 and thus facilitates detoxifying liver functions", again without data retrievable here.3
Regulatory and anti-doping status
Sources in this part
The WADA 2026 Prohibited List names "Bromantan" under S6 Stimulants, in the S6.A group of non-specified stimulants.2 The S6 class is marked as prohibited in-competition.2 Oliynyk and Oh state that bromantane metabolites "can be found in urine, even in two weeks after administration", which they describe as important for doping control.3 The 1997 Lancet letter by Burnat and colleagues is titled "Bromontan, a new doping agent".4 Oliynyk and Oh give Russia as the place where it is certified as a drug under the name Ladasten.3 No label was identified in DailyMed, which returned no label for "bromantane" on 16 November 2026; EMA records were not searched.
What is not known
Human pharmacokinetics are not established in the sources retrieved: no numeric half-life, and the review's bioavailability and time-to-peak figures differ from the app's.3 The Russian trial records retrieved give few numbers, most name no comparator or give no participant count, and none gives a funding statement, so effect sizes against placebo cannot be reported. Whether the Parkinson's disease and irritable bowel syndrome studies found any benefit cannot be stated from their records.15,16 The mechanistic findings are from rats, mice or tissue, and the 8-hour dopamine figure in the app's notes was not checked against a retrievable summary.6 No long-term human safety, tolerance or dependence data from trials with full reports were retrieved.
Frequently asked questions
What is the half-life of bromantane?
The app lists a half-life of about 12 hours, and the sources retrieved give no numeric human half-life.3 The app's notes say the figure is modelled by analogy to amantadine and is not a measurement.
What is the bioavailability of bromantane?
The app lists 85%, while the Oliynyk and Oh review gives 42% by mouth.3
How long does bromantane take to reach its peak level?
The app lists about 3 hours, and the Oliynyk and Oh review gives 2.75 hours in women and 4.0 hours in men.3
Is bromantane banned by WADA?
What is Ladasten?
Ladasten is the Russian trade name for bromantane, which Oliynyk and Oh describe as certified in Russia as a drug.3 The app's notes state that it is not approved anywhere else.
Has bromantane been studied in people?
Does bromantane affect dopamine?
What dose was used in the Russian trials?
The 728-patient multicentre study reports a daily dose from 50 to 100 mg for 28 days.1 The app's typical range is also 50 to 100 mg per day.
What is the 1997 Lancet letter on bromontan?
A 1997 letter in The Lancet by Burnat and colleagues carries the title "Bromontan, a new doping agent".4
Guides, tools and comparisons
References
- Voznesenskaia TG, Fokina NM, Iakhno NN. Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten. Zh Nevrol Psikhiatr Im S S Korsakova 2010;110(5 Pt 1):17-26. PMID 21322821
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul) 2012;20(5):446-56. PMID 24009833
- Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F. Bromontan, a new doping agent. Lancet 1997;350(9082):963-4. PMID 9314900
- Kudrin VS, Sergeeva SA, Krasnykh LM, et al. The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain. Eksp Klin Farmakol 1995;58(4):8-11. PMID 7580761
- Grekhova TV, Gainetdinov RR, Sotnikova TD, et al. The effect of bromantane on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study. Biull Eksp Biol Med 1995;119(3):302-4. PMID 7795203
- Vakhitova IuV, Iamidanov RS, Seredinin SB. Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain. Eksp Klin Farmakol 2004;67(4):7-11. PMID 15500036
- Mikhaylova M, Vakhitova JV, Yamidanov RS, et al. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology 2007;53(5):601-8. PMID 17854844
- Morozov IS, Klimova NV, Karpova TD, Shestopalov SS. The characteristics of the neuropsychotropic activity of bromantane in laboratory animals. Eksp Klin Farmakol 1999;62(2):3-6. PMID 10340117
- Sergeeva SA, Krapivin SV, Losev AS, Morozov IS. Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane. Biull Eksp Biol Med 1995;119(3):305-8. PMID 7795204
- Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB. Pilot clinical trial of ladasten. Eksp Klin Farmakol 2006;69(4):10-5. PMID 16995430
- Neznamov GG, Siuniakov SA, Teleshova SE, et al. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo). Zh Nevrol Psikhiatr Im S S Korsakova 2009;109(5):20-6. PMID 19491814
- Neznamov GG, Bochkarev VK, Siuniakov SA, Grishin SA. Characteristics of ladasten effect in neurasthenia patients with various EEG parameters. Eksp Klin Farmakol 2008;71(4):18-25. PMID 18819436
- Neznamov GG, Bochkarev VK, Reutova MA, Shabanova AA, Siuniakov SA. Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types. Eksp Klin Farmakol 2012;75(5):7-13. PMID 22834121
- Sarycheva TN, Rybak VA, Kurushina OV. Ladasten in the management of non-motor symptoms of Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova 2011;111(1):85-7. PMID 21434470
- Uspenskii IuP, Fominykh IuA. Prospects for using ladasten preparations in patients with irritable bowel syndrome. Eksp Klin Gastroenterol 2010;(10):75-9. PMID 21434378
- Bugaeva LI, Verovskii VE, Iezhitsa IN, Spasov AA. An acute toxicity study of bromantane. Eksp Klin Farmakol 2000;63(1):57-61. PMID 10763112